Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.
The European General Court dismissed an appeal from Novartis over one of its figurative trademarks yesterday, January 31.
Japan-based Abe & Partners has promoted Michiko Kinoshita as partner and Tomohiro Kazama as counsel.
Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.
Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.
CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.
The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.
Medical device firm Cooper Companies has agreed to acquire the global rights to Teva’s Paragard intrauterine device (IUD) for $1.1 billion.
AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.